Hangzhou Tongee Medical Technology Co., Ltd. is a national high-tech enterprise dedicated to building an innovative platform for innovative gastrointestinal therapies and related medical equipment, disease management and solutions. After years of unremitting efforts, we have successfully developed a number of new medical technologies for metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease. The "Gastric Bypass Stent System" we pioneered is the world's first medical device for intestinal interventional treatment of metabolic diseases. In January 2024, the device was approved as a innovative Class III medical device in China (the world's first) and received Breakthrough Device Designation from the US FDA in October 2024. As of August 2025, it had completed medical device registration in six countries: Indonesia, Thailand, Vietnam, Malaysia, Saudi Arabia, and Ecuador. This milestone product will provide more convenient, safe and effective treatment options for patients with metabolic diseases. In addition, we have established multiple technology platforms and ISO13485-certified R&D, quality, manufacturing, and supply chain management system. As of August 2025, there are over 140 patent applications in Tongee. Tongee is an innovation-driven and doctor- and patient-centered company dedicated to ushering in a new era of interventional treatment for metabolic diseases and creating a better life for patients around the world!